The LDN 2021 Conference Recordings Now Available with up to 29 CME Credits [More Details]
Low-dose Naltrexone as a Treatment for Chronic Fatigue Syndrome (Abstract)
Low-dose Naltrexone as a Treatment for Chronic Fatigue Syndrome
BMJ Case Reports
06 January 2020
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn’s disease, fibromyalgia and Gulf War Illness. Despite numerous internet reports of response to low-dose naltrexone (LDN), no clinical trials exist in people with chronic fatigue syndrome. This condition is characterised by chronic profound fatigue, postexertional malaise, pain and autonomic and neurocognitive disturbances. This series of three case reports compiled by people with long-term ill-health due to chronic fatigue syndrome shows the range of responses they observed when taking LDN, from life changing to a reduction in some symptoms only. Treatment doses ranged from 4 to 12 mg. Clinical trials may be warranted to explore the potential use of naltrexone in people with these debilitating illnesses which currently have no licensed treatments available.
Keywords: naltrexone, chronic disorders, Crohn’s disease, fibromyalgia, Gulf War Illness, chronic fatigue syndrome, LDN
Keywords by Erin Williams, student, St. Louis College of Pharmacy